We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+17.33%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$961M
AUM Growth
+$374M
Cap. Flow
-$4.74M
Cap. Flow %
-0.49%
Top 10 Hldgs %
44.93%
Holding
194
New
69
Increased
29
Reduced
39
Closed
48

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$24.6M
2
AGN
Allergan plc
AGN
+$24.2M
3
MRK icon
Merck
MRK
+$22.3M
4
AMGN icon
Amgen
AMGN
+$17.6M
5
ENDP
Endo International plc
ENDP
+$17.6M

Top Sells

Rank Stock Value
1
NVS icon
Novartis
NVS
+$33.6M
2
SHPG
Shire pic
SHPG
+$20.7M
3
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$18.2M
4
BIIB icon
Biogen
BIIB
+$11.8M
5
ISRL
Isramco Inc
ISRL
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 53.73%
2 Technology 2.61%
3 Industrials 1.8%
4 Consumer Discretionary 1.51%
5 Utilities 1.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VFC icon
76
VF Corp
VFC
$5.63B
$3.18M 0.33%
+44,785
New +$3.1M
ORBK
77
DELISTED
Orbotech Ltd
ORBK
$3.15M 0.33%
196,622
-84,250
-30% -$1.34M
AEGR
78
DELISTED
Aegerion Pharmaceuticals
AEGR
$3.14M 0.33%
120,000
-40,000
-25% -$1.02M
PRGO icon
79
Perrigo
PRGO
$1.4B
$3.05M 0.32%
+18,400
New +$2.93M
NBIX icon
80
Neurocrine Biosciences
NBIX
$16.8B
$2.98M 0.31%
75,000
+25,000
+50% +$894K
MRTX
81
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.93M 0.31%
+100,000
New +$2.35M
KERX
82
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$2.93M 0.3%
230,000
+30,000
+15% +$386K
CLDX icon
83
Celldex Therapeutics
CLDX
$2.99B
$2.93M 0.3%
+7,000
New +$2.5M
RCPT
84
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$2.89M 0.3%
17,500
-12,500
-42% -$1.58M
AERI
85
DELISTED
Aerie Pharmaceuticals
AERI
$2.82M 0.29%
90,000
+1,484
+2% +$43K
EPZM
86
DELISTED
Epizyme, Inc
EPZM
$2.82M 0.29%
+150,000
New +$3.1M
MDCO
87
CALL
DELISTED
Medicines Co
MDCO
$2.8M 0.29%
+1,000
New +$28.1K
MDCO
88
DELISTED
Medicines Co
MDCO
$2.8M 0.29%
100,000
– –
TTPH
89
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$2.75M 0.29%
+3,750
New +$2.82M
IMDZ
90
DELISTED
Immune Design Corp.
IMDZ
$2.73M 0.28%
+129,440
New +$3.38M
TVTX icon
91
Travere Therapeutics
TVTX
$5.2B
$2.67M 0.28%
+111,392
New +$1.7M
ATRA icon
92
Atara Biotherapeutics
ATRA
$75.5M
$2.64M 0.28%
+2,543
New +$1.68M
PAY
93
DELISTED
Verifone Systems Inc
PAY
$2.64M 0.27%
+75,545
New +$2.62M
TRVN
94
DELISTED
Trevena, Inc.
TRVN
$2.56M 0.27%
627
-253
-29% -$928K
QURE icon
95
uniQure
QURE
$3.03B
$2.49M 0.26%
102,415
-66,000
-39% -$1.44M
OTIC
96
DELISTED
Otonomy, Inc.
OTIC
$2.48M 0.26%
+70,000
New +$2.39M
ADVM
97
DELISTED
Adverum Biotechnologies
ADVM
$2.43M 0.25%
+6,000
New +$2.54M
SNA icon
98
Snap-on
SNA
$21.2B
$2.26M 0.23%
15,340
-5,800
-27% -$816K
TXMD icon
99
TherapeuticsMD
TXMD
$23.5M
$2.21M 0.23%
+7,300
New +$1.78M
SGMO
100
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$2.19M 0.23%
140,000
-60,000
-30% -$928K
2 3
4
5 6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2015 Portfolio in Review

As of Q1 2015, Sphera Funds Management held 194 positions worth $961M, up 64% from $587M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sphera Funds Management's Q1 2015 filing shows 69 new, 29 increased, 39 reduced and 48 closed positions. Its largest new stake was AbbVie: 407,000 shares worth $23.8M. The largest sale was Novartis, an estimated $33.6M.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, down from 63% a quarter earlier, followed by Technology and Industrials.

  • Sphera Funds Management's largest Q1 2015 buy was AbbVie: 407,000 shares worth $23.8M.
  • Sphera Funds Management added most to Allergan plc in Q1 2015, an estimated $24.2M increase.
  • Sphera Funds Management's biggest Q1 2015 reduction was Novartis, cutting an estimated $33.6M.
  • Sphera Funds Management fully exited SALIX PHARMACEUTICALS LTD DEL in Q1 2015, selling an estimated $18.2M.
  • Sphera Funds Management's ten largest holdings make up 45% of its $961M portfolio in Q1 2015.
  • Sphera Funds Management opened 69 new positions and closed 48 in Q1 2015.
  • Sphera Funds Management's portfolio value rose 64% quarter-over-quarter to $961M.

Based on Sphera Funds Management's 13F filing for Q1 2015, filed 11 May 2015.